DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

Referenz

Baselga J, Piccart M, Gnant M et al.
Minimal molecular alteration in PI3KCA, FGFR1 and CCND1 is associated with increased benefit from everolimus in hormone receptor-positive, HER2-advanced breast cancer: Insights from the BOLERO-2 trial.

Eur J Cancer 2013;
49: S404-S405

Bibliographische Angaben herunterladen

Suchen in: